Biofrontera Inc (BFRI)

$0.85 -0.01 (-1.70%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	10.07M
Revenue (ttm)	37.32M
Net Income (ttm)	-17.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	14.76
Profit Margin	-47.59%
Debt to Equity Ratio	-1.73

Volume	59,300
Avg Vol	543,880
Day's Range	N/A - N/A
Shares Out	11.65M
Stochastic %K	56%
Beta	0.61
Analysts	Strong Sell
Price Target	$6.00

Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatmen...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 781 245 1325

Website: www.biofrontera-us.com

Address:

120 Presidential Way, Suite 330, Woburn, United States